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while controlling for length of diagnosis, sociodemographics, and general health char-
acteristics. Results: A total of 346 respondents were included in the analysis; mean 
age was 55 years, 55% were male, and 55% were employed. Pain severity was 3/10 
for the 1st quartile, 5/10 for the median, and 7/10 for the 3rd quartile of this sample. 
Increasing severity was associated with lower scores for mental (MCS) and physi-
cal component summaries (PCS) and SF-6D health utility, higher depression (PHQ-9) 
and anxiety (GAD-7) scores, greater absenteeism and presenteeism, greater activity 
impairment, more healthcare provider visits, and more emergency visits (all p< 0.05). 
As pain severity increased from the 1st to 3rdquartile, MCS, PCS, and SF-6D all declined 
more than the minimally important difference, while work and activity impairments 
approximately doubled. ConClusions: The impact of CLBP on HRQoL, depression 
and anxiety symptoms, impairment to work and daily activities, and healthcare 
use increases with the severity of pain. Interventions reducing severity of pain may 
improve numerous health outcomes even if the pain cannot be eliminated.
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objeCtives: Psoriasis is prevalent in approximately 3% of the population, and often 
results in significant quality of life losses. The aim of this study was to investigate 
the relationship between disease severity and quality of life (QOL) measured by the 
psoriasis area severity index (PASI) and EQ-5D, respectively. Methods: Longitudinal 
data from a population-based registry in Sweden (PsoReg) were analysed. PsoReg 
includes patients with moderate to severe psoriasis receiving systemic treatment 
from a specialist with data available from 2006 to 2014. The analysis was conducted 
using all complete observations for adult patients at each healthcare contact date. A 
fixed effects (FE) model was estimated, where time-invariant patient-specific effects 
were modelled. Time-invariance refers to variables that do not change over time, 
such as sex or personality. PASI, PASI squared, age, body mass index, smoking status, 
and presence of psoriatic arthritis were included in the regression as independent 
variables. PASI squared accounts for a nonlinear relationship between PASI and 
EQ-5D. The model was tested for the appropriateness of random effects and exist-
ence of group-wise homoscedasticity, both of which were rejected at an alpha level 
of 0.01. Therefore the final model used FE and robust standard errors. Results: The 
estimation utilised 15,099 observations in 3,838 groups, resulting in an average of 3.9 
observations per patient. The results indicate that each unit increase in PASI is cor-
related with a reduction in EQ-5D, but at a decreasing rate: the estimates of PASI and 
PASI squared were -0.0178 (p< 0.001) and 0.0002 (p< 0.001) respectively. This implies 
that an increase in PASI of 10 (20) units results in a decrease in EQ-5D of 0.1571 
(0.2717) holding other variables constant at their respective means. The (adjusted) 
R2 was (0.5279) 0.6481. ConClusions: QOL in psoriasis patients is decreasing as 
disease severity increases, but at a decreasing rate.
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objeCtives: Total hip and knee arthroplasty operations are commonly performed 
to improve patients’ quality of life. The aim of this study is evaluation of patients’ 
quality of life of preoperation and early postoperation after total hip and knee 
arthroplasty. Methods: This study included 26 patients undergoing total hip and 
knee arthroplasty. After the literature review, 15-items questionnaire was prepared 
for collecting data related to sociodemographic, medical and functional status 
information, including age, sex, previous hip and knee arthroplasty and pain level. 
Quality of life were measured by using the EQ-5D and Visual Analog Scale (VAS). 
During the study, questionarries were administered to patients 2 times: one week 
prior to operation and 45 days following operation. Results: The average age of 
participants was 67,12 years (SD: 10,527). Participants were composed of 80,8% 
females and 19,2% males. Small improvements were reported for pain and func-
tional status after the operations, while large changes were seen in the patients’ 
quality of life. The EQ-5D scores improved significantly preoperatively to postop-
ertively (p< 0,05) (0,322 vs 0,844). Similarly, there was a significant improvement in 
VAS scores preoperatively to postoperatively (p< 0,05) (4,72 vs 7,78). ConClusions: 
Total hip and knee arthroplasties are well accepted as reliable and suitable surgical 
procedures to return patients to function and improve the quality of life of patients’.
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objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, 
progressive, debilitating and life-threatening neurodegenerative disease. The 
purpose of this study was to assess the health-related quality of life (HRQoL) fac-
tors for TTR-FAP patients. Methods: HRQoL was measured using the validated 
EuroQoL five dimensions three levels (EQ-5D-3L) questionnaire being the index 
score calculated trough the Portuguese scoring algorithm. TTR-FAP symptomatic 
patients specific data (n = 566) extracted from Transthyretin Amyloidosis Outcomes 
Survey (THAOS) registry. Demographic variables include gender and age. Clinical 
variables include disease onset (early/late), polyneuropathy disability (PND) score, 
liver transplant and pharmacologic treatment. Econometric analyses were car-
ried out to identify factors that impact TTR-FAP HRQoL. Results: In a scale from 
-0.50 to 1.00 the average utility score 0.50(0.37) for symptomatic TTR-FAP patients. 
Within TTR-FAP population, significant statistical effect (p-value < 0.005) was 
gain category (3.45, 3.97) and increased with increasing categorical weight loss: B 7.63, 
7.61; C 10.61, 10.92; D 12.61, 16.50; E 17.27, 15.35. Changes in SF-36 physical component 
summary scores, but not mental component summary scores, followed a similar pat-
tern. ConClusions: We observed higher proportions of subjects achieving greater 
categorical weight loss with liraglutide 3.0 mg versus placebo as adjunct to D&E. With 
greater categorical weight loss, greater improvements in IWQOL-Lite total and SF-36 
physical component summary scores were observed.
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objeCtives: Sickle-cell disease (SCD) manifests clinically as severe pain episodes 
in various locations of the body. Patients with SCD also experience chronic daily 
pain, which profoundly affects quality of life. Cognitive interviews were conducted 
to evaluate comprehension and usability of a modified version of the Faces Pain 
Scale-Revised (Modified FPS-R), which asks children to rate their worst pain today 
using an electronic device. Methods: In-person interviews were conducted in the 
US with children aged 4-17 years with SCD and their parent/legal guardian. Children 
who were unable to read or needed guidance were assisted by their parent/legal 
guardian using written administration guidelines. Children were asked questions 
about their pain experience, understanding of the instrument, and ability to use 
the electronic device. Parents/legal guardians were debriefed on the administra-
tion guidelines, assisting their child, use of the electronic device, and their child’s 
pain experience. Results: The sample included 22 African American children (13 
females/9 males; 7= 4-5 year-olds, 12= 6-11 year-olds and 3= 12-17 year-olds). Pain 
was most commonly reported to occur in the legs, back, arms, stomach, or head. 
Those aged ≥ 7 years were able to demonstrate good understanding of the Modified 
FPS-R item and response scale and ability to use the electronic device. Children 4-6 
years were generally not familiar with “discomfort” and many did not know the 
meaning of “pain”. It was unclear whether these children were able to consider their 
worst pain over the course of the day and respond accordingly. Parents/legal guard-
ians noted that the instrument instructions were clear and that the administration 
guidelines provided simplified, standardized direction for young children and those 
unable to read without assistance. ConClusions: The Modified FPS-R used with 
the administration guidelines where parental assistance is needed, is an appropri-
ate measure of sickle-cell pain over the course of a day for children aged ≥ 7 years.
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objeCtives: To identify patient-reported outcomes (PROs) evaluating quality of 
life (QoL) in Gaucher Disease (GD) after formation of Rare-Diseases Program in 
2010 by the Center for Drug Evaluation and Research under United States Food 
and Drug Administration with a mission to acknowledge patient’s perceptions on 
treatment benefits. Methods: Embase® and MEDLINE®databases were searched 
from January 2010 to May 2015. Studies published in English language were included 
irrespective of study designs by two independent reviewers with discrepancies rec-
onciled by a third independent reviewer. Results: Out of 325 studies retrieved from 
biomedical databases, only nine studies reporting seven different PRO instruments 
were included. Details of study conduct were adequately reported with no signifi-
cant difference between treatment groups. Six generic instruments were identified 
from the included studies, Short Form Health Survey with 36-items (SF-36; 5 studies), 
12-items (SF-12; 1 study), the European Quality of Life - Five Dimensions (EQ-5D; 
2 studies), Functional Assessment of Chronic Illness Therapy - Fatigue (FACT-F; 1 
study), Brief Pain Inventory (BPI; 1 study), and the Visual Analogue Scale (VAS; 1 
study). Only one study used the disease-specific Type 1 Gaucher Disease - Disease 
Severity Scoring System (GD-DS3) providing a reliable method of assessing both 
intra- and inter-patient severity indicating an impact of pain on the QoL. Overall, 
the results correlated with clinical outcomes in GD patients demonstrating poorer 
physical functioning than healthy controls. A review of HTA submissions showed 
that current evidence on QoL was not sufficient to assess disease impact with the 
French HTA agency (HAS) particularly encouraging the need to assess QoL to support 
evidence on treatment effects. ConClusions: Variability in use of PRO instruments 
was seen among the included studies. Disease specific PRO measures are highly 
acceptable and need to be developed in orphan disease for better evaluation of QoL.
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objeCtives: To quantify the impact of pain severity on patient-reported out-
comes among individuals diagnosed with chronic lower back pain (CLBP) in 
Japan. Methods: Data came from the 2012 Japan National Health and Wellness 
Survey (N= 29,997), a web-based survey of individuals in Japan aged ≥ 18 years. 
This analysis included respondents diagnosed with lower back pain of ≥ 3 months’ 
duration. Measures included the SF-36v2, Patient Health Questionnaire (PHQ-9), 
Generalized Anxiety Disorder 7-item (GAD-7) scale, Work Productivity and Activity 
Impairment questionnaire, and self-reported all-cause healthcare visits (6 months). 
Generalized linear models with appropriate link functions were used to assess the 
relationship between outcomes and severity of pain in the prior week as reported on 
a visual analog scale ranging from 0 (No pain) to 10 (Pain as bad as you can imagine) 
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Care on prevention and treatment of rare (orphan) diseases’ has been recently 
issued. It governs the measures of OD prophylaxis. Methods: According to the 
Law, in order to improve OD patient care, a work on medical and technological docu-
ments on such topics as mucopolysaccharidosis, Gaucher disease, phenylketonuria, 
hemophilia was launched. The development of medico-technological documents 
was done in a few steps. Firstly, the search for clinical guidelines was conducted 
in the GIN library and other sources. Secondly, the primary selection and appraisal 
with AGREE II instrument have been carried out. The next step was adaptation of 
clinical guidelines and development of clinical protocols of the medical care. It 
was conducted by multidisciplinary working groups including leading specialists 
in clinical genetics, health care managers and patients organizations. Results: 
Today the clinical protocols of treatment of mucopolysaccharidosis patients, based 
on evidence of the effectiveness of medical technologies, pharmacotherapy and 
organizational principles of its provision, were approved. The documents contained 
modern approaches for diagnostics and treatment of mucopolysaccharidosis, which 
are ajusted to the health care system of Ukraine. ConClusions: Harmonization 
of treatment practices of OD in Ukraine with international best practice will bring 
the treatment of these states in Ukraine to a new level and provide thorough meas-
ures aimed at the development of screening and prevention programs, diagnostics 
and treatment, as well network collaboration among health services, educational 
institutions, public etc.
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objeCtives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder 
that can cause multi-organ damage, leading to reduced life expectancy, lower qual-
ity of life, and high medical expenditures. Therefore, long-term and comprehensive 
disease management and monitoring are important. This study aimed to examine 
treatment pattern, quality of SLE care, and utilization and costs of medical care of 
SLE patients. Methods: The National Health Insurance Research Database was 
adopted to identify patients diagnosed with SLE before 2010 through their eligibility 
for catastrophic illness of SLE, and examine their use and costs of health services 
in 2010. Logistic regression models and generalized linear models were adopted 
for analyses. Results: The majority of 744 patients with SLE was female (85%), 
older than 40 years old (54%), and having been diagnosed with SLE for more than 
five years (68%). Sixty-one percent of them received corticosteroids, 59% received 
antimalarials, and 36% received immunosupressants. Annual tests for complete 
blood count, creatinine, and serum levels of complement component C3/C4 and 
anti-dsDNA antibodies were received by 85%, 78%, and 76% of the subjects, respec-
tively. Forty-four percent of them received annual evaluation of cardiovascular risk, 
and 3% of them received influenza vaccination. Average number of outpatient visit 
was 33.47, and SLL-related visit was 12.82. Twenty-two percent of them were admit-
ted to hospital during the year, and the average number of hospital admission was 
0.48. The average annual medical cost was NTD105,059, and the average SLE-related 
medical cost was NTD29,770. Shorter time since SLE diagnosis was associated with 
more intense treatment, better adherence to recommendations for annual tests, and 
higher SLE-related costs. ConClusions: This study identified treatment pattern, 
quality of SLE care, and use and costs of patients with SLE. Disease management 
and monitoring need to be improved.
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objeCtives: To investigate the global perspectives of Turkish Rheumatologists 
regarding expected FMF prevalence, undiagnosed patients ratio, arguments in diag-
nostic procedure and management of FMF. Methods: A questionnaire consist of 
estimated frequency, diagnostic modalities and follow up characteristics in addition 
to therapeutic approach was set up. Even though a regular colchicine use, ≥ 1 attack /
month during 6 months was accepted as colchicine resistant. All members of Turkey 
Society for Rheumatology from country wide (n= 235) were invited to fill in the 
web-based questionnaire for FMF by e-mail. Totally 108 members (45.9%) answered 
the questionnaire. Results: Estimated prevalence was median 0.2% (IQR25-75: 
0.1-0.7) for FMF. Only 51.4±19.0 % of these patients had been diagnosed according 
to Rheumatologists opinion. Time to diagnosis from the first symptom was more 
than 3 years in 49.5% of patients. Description of typical attacks in anamnesis is the 
most frequent parameter in diagnosis of patients whereas in 26.7 %of patients MEFV 
mutations were required for diagnosis. 53.5 ±21.3 % of patients were on regular 
follow up and 75.7% of these follow up was with a 3-6 months period. Frequency 
of Colchicine resistant patients was expected in 7.2%. The use of biologic agents in 
the patients followed up by these physicians was expected as 3.4%. ConClusions: 
Since half of the estimated prevalence was expected as undiagnosed and patients 
have a 3-years delay in diagnosis, Medical and Social Activities are required to 
increase the awareness of FMF. Less than 5 percent of patients required biologic 
agents in FMF.
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observed for age, pharmacologic treatment and disease severity. No significant 
statistical effect was observed for gender, late onset patients (> 50 years) and liver 
transplant. ConClusions: The preference-based utility measures used in this 
study adequately disentangle TTR-FAP impact on patient’s quality of life and allow 
discriminating across different TTR-FAP clinical severity states, interventions and 
demographic characteristics. Assuming that these values represent the patients’ 
preferences and the utility associated with their health state, the results presented 
in this study may be used in future health technologies cost-utility studies.
PSY98
healTh-RelaTeD QualiTY of life (hRQol) in SPleneCToMizeD iMMune 
ThRoMBoCYToPenia (iTP) PaTienTS – a TaRgeTeD liTeRaTuRe Review
Lebioda A1, Batscheider A2
1Amgen GmbH, Munich, Germany, 2IMS Health, Munich, Germany
objeCtives: Immune thrombocytopenia (ITP) is associated with a risk of spontane-
ous and excessive bleeding. Among the treatment options are medical therapies and 
splenectomy – a major intervention with lifelong consequences for the patient. Both 
ITP and ITP-treatment may impact health-related quality of life (HrQoL); therefore, 
a literature search was conducted to assess HrQoL of splenectomized compared to 
non-splenectomized ITP patients. Methods: A targeted literature search was con-
ducted via Ovid (Medline, Embase, and Cochrane) in September 2014. Search strings 
were based on PICO-criteria (Patient, Intervention, Comparison and Outcomes). 
Inclusion criteria were: studies of adult patients with ITP that contained information 
on HrQoL; clinical trials, RCTs, meta-analyses, observational trials, retrospective 
studies or systematic reviews; manuscripts and congress abstracts in English or 
German language. Results: The search identified 148 potentially relevant publica-
tions. After removing duplicates, 120 titles and abstracts were screened. Following 
the title/abstract screening, a full text screening (n= 21) identified six relevant pub-
lications. HrQoL was assessed in these six publications using generic (SF-36, n= 2; 
EQ-5D, n= 1) and disease-specifc (ITP-PAQ, n= 4) instruments. Two studies using 
generic instruments reported no difference in HrQoL between splenectomized and 
non-splenectomized patients. Of the four studies using the ITP-PAQ, two reported 
no difference and two found worse HrQoL in splenectomized versus non-splenec-
tomized patients. In the only study that included both generic (SF-36, EQ-5D) and 
ITP-specific measures, results were inconsistent, as they varied in outcomes. Overall 
detailed results were not always provided and HrQoL was not reported according 
to response to therapy in any study. ConClusions: The impact of splenectomy 
on HrQoL in patients with ITP is inconclusive and inconsistently reported in the 
literature, due to use of different instruments, diverse patient characteristics, and 
pooling of data among responding and non-responding patients. Further studies are 
needed to address this question within clearly-defined populations.
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objeCtives: Treatment for children with GHD involves daily injections which 
may begin at a very early age and continue throughout childhood. However, the 
treatment burden (TB) for children and their parents has not been examined. The 
purpose of this study was to support the content validity of a new GHD-specific TB 
measure, with versions for patient-reported outcome (PRO) for older children, and 
observer-reported outcome (ObsRO) and PRO for parents/guardians. Methods: 
Focus groups and interviews were conducted with 39 children (aged 8–12) with 
GHD, 31 parents of children (aged 4–12) and eight clinical experts in three countries 
(Germany, UK, US). Interviews were analysed and coded using adapted grounded 
theory. A conceptual model of TB was developed and items were generated and 
then cognitively debriefed. Results: Qualitative analysis found saturation was 
reached with three domains for child TB and two domains for parent TB. Child 
domains (and major proximal subdomains) were: Physical (pain, 33% and bruis-
ing, 19%), Interference (Interference with overnight or other activities, 29% and 
Time needed emotionally to prepare for treatment, 23%) and Emotional (Worry, 
about injections, 37%, Unhappiness with injection frequency, 25%, and Fear, 22%). 
Parent TB domains were Emotional (Worry or anxiety about treatment or treat-
ment administration, 58% and Worry about causing pain, 42%) and Interference 
(Time spent preparing and administering injection, 42%, Interference with travel/
vacation, 42%, and Interference with daily/family routines, 35%). The items were 
cognitively debriefed in a new sample (N= 26: 13 children, 13 parents) and, based on 
findings, it was determined that the PRO version was appropriate for children aged 
9–12. The final measure includes 17 items (child PRO and parent ObsRO versions) 
with a 12-item parent PRO module. ConClusions: The conceptual validity of the 
TB-CGHD is supported by these qualitative findings and the measure is now ready 
for psychometric validation.
SYSTeMiC DiSoRDeRS/ConDiTionS – health Care use & Policy Studies
PSY100
TowaRDS CReaTing a naTional SYSTeM of CaRe foR PaTienTS wiTh 
oRPhan DiSeaSeS
Rubtsova I, Shilkina O, Lishchyshyna O
State Expert Centre of the Ministry of Health of Ukraine, Kyiv, Ukraine
objeCtives: There is no integrated approach to the problem of orphan diseases 
(OD) in Ukraine. Diagnosis of these illnesses is often complicated and delayed, the 
treatment is often ineffective because of the lack and unavailability of essential 
medicines and methods of treatment, the quality of life for most patients remains 
poor. The Law of Ukraine ‘On amendments to the Basic Laws of Ukraine on Health 
